Advertisement
Screener

MEREO BIOPHARMA GROUP PLC (MREO) ROA

Mereo BioPharma Group plc ROA

Return on assets (ROA) is the profit a company earns for every dollar of assets it uses, shown as a percentage. It is net income divided by total assets, and the table shows both amounts. Because assets are funded by lenders as well as shareholders, ROA is not inflated by borrowing the way ROE can be, and it is naturally lower for businesses that need many factories, stores or other assets. Quarterly points divide the trailing four quarters of net income by the balance at that quarter end; annual points divide the filed fiscal-year net income by the fiscal-year-end balance.

  • Mereo BioPharma Group plc roa for the quarter ending 2026-06-30 was -80.94%, a change of -1.83% year-over-year.
  • Mereo BioPharma Group plc roa for the quarter ending 2026-03-31 was -87.93%, a change of -18.86% year-over-year.
  • Mereo BioPharma Group plc roa for the quarter ending 2025-12-31 was -91.20%, a change of -34.58% year-over-year.
  • Mereo BioPharma Group plc roa for the quarter ending 2025-09-30 was -77.56%, a change of -26.50% year-over-year.
  • Mereo BioPharma Group plc roa for fiscal 2025 was -91.20%, a change of -34.58% from fiscal 2024.
  • Mereo BioPharma Group plc roa for fiscal 2024 was -56.62%, a change of -12.31% from fiscal 2023.
  • Mereo BioPharma Group plc roa for fiscal 2023 was -44.31%, a change of 10.23% from fiscal 2022.
  • Mereo BioPharma Group plc roa for fiscal 2022 was -54.54%.
Available history
2022-12-31 to 2026-06-30
Data captured

Historical ROA

DateROANet income 12 monthNet income 3 monthTotal assets
2026-06-30-80.94%-$28.1M-$7.00M$34.71M
2026-03-31-87.93%-$35.71M-$6.72M$40.61M
2025-12-31-91.20%-$41.88M$76.41M$45.92M
2025-09-30-77.56%-$41.57M-$7.02M$53.6M
2025-06-30-79.11%-$49.55M-$14.62M$62.63M
2025-03-31-69.07%-$47.19M-$12.89M$68.32M
2024-12-31-56.62%-$43.25M$79.46M$76.39M
2024-09-30-51.06%-$45.32M-$15.00M$88.75M
2024-06-30-38.33%-$36.85M-$12.26M$96.13M
2024-03-31-47.09%-$26.34M-$8.95M$55.94M
2023-12-31-44.31%-$29.47M$49.82M$66.5M

Annual ROA

DateROANet income 12 monthTotal assets
2025-12-31-91.20%-$41.88M$45.92M
2024-12-31-56.62%-$43.25M$76.39M
2023-12-31-44.31%-$29.47M$66.5M
2022-12-31-54.54%-$42.22M$77.41M

Similar stocks

Stock NameCountryMarket CapPE Ratio
Greenwich LifeSciences, Inc. (GLSI)United States$0.267B-15.02
Sagimet Biosciences Inc. (SGMT)United States$0.279B
Akebia Therapeutics, Inc. (AKBA)United States$0.255B-10.35
Upstream Bio, Inc. (UPB)United States$0.284B-2.42
Perspective Therapeutics, Inc. (CATX)United States$0.284B-3.34
Contineum Therapeutics, Inc. (CTNM)United States$0.289B-4.40
Fulcrum Therapeutics, Inc. (FULC)United States$0.289B-3.28
Lyell Immunopharma, Inc. (LYEL)United States$0.248B-1.32
Pyxis Oncology, Inc. (PYXS)United States$0.244B
ROCKET PHARMACEUTICALS, INC. (RCKT)United States$0.296B-21.78